Monoclonal Antibody Hb3: A Marker For Colon Cancer Progression Or As A Therapeutic Target?

Main Category: Colorectal Cancer
Also Included In: Genetics;  Biology / Biochemistry
Article Date: 04 May 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Healthcare Prof:1 star

1 (1 votes)


There are a number of researchers who are searching for useful tumor markers to indicate cure. Antigens are being applied as an effective target in clinical therapy. Hb3 is an anti-colorectal cancer monoclonal antibody produced in the researchers' laboratory, and whose sensitivity and specificity are superior to that of anti-CEA. Previous results have showed that CA-Hb3 may be useful in the clinical diagnosis of colorectal cancer.

This study, carried out by a team led by Professor G. C. Li, is described in a research article that will be published on March 14, 2008, in the World Journal of Gastroenterology.

To comprehensively identify the proteins of the tumor-associated antigen Ca-Hb3 which is recognized by colorectal carcinoma monoclonal antibody Hb3, Ca-Hb3 was isolated by SDS-PAGE followed by digestion with trypsin. The trypsin peptides were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Applying bioinformatics to analyze the proteins which were identified by mass spectrometry, Ca-Hb3 was identified as CKAP4-similar protein by nano-HPLC tandem mass spectrometry analysis. The molecular weight of CKAP4-similar protein is 62.02 kDa, including one hydrophobic region, one transmembrane domain, five coiled coils, four glycosylation sites and forty-nine phosphorylation sites. CKAP4-similar protein has high homogeneity with Np63A, and the characteristic expression of agrNp63 alpha that is considered a potential oncogene in the isoforms of p63 is similar to Ca-Hb3.

Np63A is an isoform of the p63 family. A number of studies have highlighted the oncogenic potential of agrNp63 alpha.agrNp63 alpha is overexpressed in several epithelial cancers, often as a result of gene amplification. The overexpression of an Np63A isoform in Rat 1A cells increases colony growth in soft agar and xenograft tumor formation in nude mice. It is hypothesized that agrNp63 alpha promotes survival and the maintenance of proliferative capacity in both epithelial stem cells and cancer cells.

###

Reference: Sun S, Guo FJ, Tong YQ, Zhu JG, Li GC.
Research on colorectal carcinoma associated antigen Ca-Hb3 by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry.
World J Gastroenterol 2008; 14(10): 1588-1591 http://www.wjgnet.com/1007-9327/14/1588.asp

Correspondence to: Guan-Cheng Li, Professor, Cancer Research Institute, Xiangya School of Medicine, Central South University, 110 Xiangya Road, Changsha 410078, Hunan Province, China.

About World Journal of Gastroenterology

World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection for providing a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. The WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

About The WJG Press

The WJG Press mainly publishes World Journal of Gastroenterology.

Source: Jing Zhu
World Journal of Gastroenterology

Article adapted by Medical News Today from original press release.
Visit our colorectal cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Jing Zhu. "Monoclonal Antibody Hb3: A Marker For Colon Cancer Progression Or As A Therapeutic Target?." Medical News Today. MediLexicon, Intl., 4 May. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/105974.php>

APA
Jing Zhu. (2008, May 4). "Monoclonal Antibody Hb3: A Marker For Colon Cancer Progression Or As A Therapeutic Target?." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/105974.php.

Please note: If no author information is provided, the source is cited instead.


Colorectal Cancer

What Is Colorectal Cancer?

Colorectal cancer is also known as bowel cancer. The UK National Health Service says colorectal cancer is the most common cancer globally today. However, the World Health Organization says it is the second most common cancer, after lung cancer. Read more...

Most Popular Articles



Follow Our Colorectal Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Colorectal Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »